Literature DB >> 33649757

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.

Hans Carl Hasselbalch1, Margitta Elvers2, Andrew I Schafer3.   

Abstract

Thrombotic, vascular, and bleeding complications are the most common causes of morbidity and mortality in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). In these disorders, circulating red cells, leukocytes, and platelets, as well as some vascular endothelial cells, each have abnormalities that are cell-intrinsic to the MPN driver mutations they harbor (eg, JAK2 V617F). When these cells are activated in the MPNs, their interactions with each other create a highly proadhesive and prothrombotic milieu in the circulation that predisposes patients with MPN to venous, arterial, and microvascular thrombosis and occlusive disease. Bleeding problems in the MPNs are caused by the MPN blood cell-initiated development of acquired von Willebrand disease. The inflammatory state created by MPN stem cells in their microenvironment extends systemically to amplify the clinical thrombotic tendency and, at the same time, preferentially promote further MPN stem cell clonal expansion, thereby generating a vicious cycle that favors a prothrombotic state in these diseases.
© 2021 by The American Society of Hematology.

Entities:  

Year:  2021        PMID: 33649757     DOI: 10.1182/blood.2020008109

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.

Authors:  Hannah Goulart; John Mascarenhas; Douglas Tremblay
Journal:  Ann Hematol       Date:  2022-03-28       Impact factor: 3.673

2.  Essential thrombocythemia complicated with simultaneous two-vessel acute myocardial infarction in the subacute phase of takotsubo cardiomyopathy: A case report.

Authors:  Yusuke Yamazaki; Yohei Numasawa; Taro Mase; Takashi Maeda; Yuhei Shinoda; Kosuke Watabe; Shoya Ono; Ayami Naito; Souichi Yokokura; Sho Haginiwa; Hidenori Kojima; Makoto Tanaka
Journal:  J Cardiol Cases       Date:  2022-07-15

3.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

4.  Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001-2018.

Authors:  Tom S M Posthuma; Otto Visser; Peter A W Te Boekhorst; Avinash G Dinmohamed
Journal:  Leukemia       Date:  2021-08-06       Impact factor: 11.528

Review 5.  Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.

Authors:  Alessandro Lucchesi; Roberta Napolitano; Maria Teresa Bochicchio; Giulio Giordano; Mariasanta Napolitano
Journal:  Int J Mol Sci       Date:  2021-10-20       Impact factor: 5.923

6.  Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.

Authors:  Tiziano Barbui; Alessandra Carobbio; Valerio De Stefano
Journal:  Res Pract Thromb Haemost       Date:  2022-02-07

7.  Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis.

Authors:  Arumugam Manoharan; Rosalie Gemmell; Lauren Cavanaugh; Noor Shadood
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 8.  The possible role of mutated endothelial cells in myeloproliferative neoplasms.

Authors:  Mirko Farina; Domenico Russo; Ronald Hoffman
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.